A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days

Published:1989-03 Issue:3 Volume:23 Page:
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother. Pharmacol.

Author:

Creaven PatrickJ.,Brenner DeanE.,Cowens J.Wayne,Huben RobertP.,Wolf RichardM.,Takita Hiroshi,Arbuck SusanG.,Razack MohamedS.,Proefrock AprilD.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/BF00267953.pdf

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytokine Biopharmaceuticals with “Activity-on-Demand” for Cancer Therapy;Bioconjugate Chemistry;2024-06-17

2. Frenemies in the Microenvironment: Harnessing Mast Cells for Cancer Immunotherapy;Pharmaceutics;2023-06-09

3. Monocyte Maturation Mediators Upregulate CD83, ICAM-1 and MHC Class 1 Expression on Ewing’s Sarcoma, Enhancing T Cell Cytotoxicity;Cells;2021-11-08

4. An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease;International Journal of Molecular Sciences;2021-09-16

5. Trial Data for Sarcoma;Cancer Regional Therapy;2019-12-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP